OPKO Health (NASDAQ:OPK) Stock Rating Reaffirmed by HC Wainwright

OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $3.00 price target on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 122.22% from the company's previous close.

Other analysts have also recently issued research reports about the stock. StockNews.com cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Friday, March 1st. Barrington Research reiterated an "outperform" rating and issued a $1.50 price target on shares of OPKO Health in a research note on Monday. Finally, Piper Sandler reiterated an "overweight" rating and issued a $5.00 price target on shares of OPKO Health in a research note on Monday.

OPKO Health Price Performance

OPK remained flat at $1.35 during trading hours on Wednesday. 11,587,389 shares of the company traded hands, compared to its average volume of 15,146,580. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $2.24. The firm has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.26. The company has a market capitalization of $940.94 million, a PE ratio of -5.40 and a beta of 1.82. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business had revenue of $181.90 million during the quarter, compared to analysts' expectations of $177.53 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. The firm's revenue was down 1.9% on a year-over-year basis. On average, equities research analysts anticipate that OPKO Health will post -0.33 EPS for the current year.

Insider Buying and Selling at OPKO Health

In related news, Vice Chairman Elias A. Zerhouni acquired 550,300 shares of the company's stock in a transaction dated Friday, January 5th. The shares were bought at an average cost of $0.93 per share, with a total value of $511,779.00. Following the completion of the transaction, the insider now directly owns 20,327,814 shares of the company's stock, valued at $18,904,867.02. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Richard M. Krasno acquired 30,000 shares of the company's stock in a transaction dated Monday, January 29th. The shares were bought at an average cost of $0.99 per share, with a total value of $29,700.00. Following the completion of the transaction, the director now directly owns 103,333 shares of the company's stock, valued at $102,299.67. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Vice Chairman Elias A. Zerhouni acquired 550,300 shares of the company's stock in a transaction dated Friday, January 5th. The stock was bought at an average cost of $0.93 per share, for a total transaction of $511,779.00. Following the completion of the transaction, the insider now directly owns 20,327,814 shares of the company's stock, valued at $18,904,867.02. The disclosure for this purchase can be found here. Insiders bought a total of 8,993,015 shares of company stock worth $8,479,069 over the last quarter. 47.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in OPKO Health by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 39,751,293 shares of the biotechnology company's stock worth $60,024,000 after acquiring an additional 428,520 shares during the period. Price T Rowe Associates Inc. MD increased its position in OPKO Health by 7.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 428,310 shares of the biotechnology company's stock worth $647,000 after acquiring an additional 29,117 shares during the period. Barclays PLC increased its position in OPKO Health by 307.6% during the fourth quarter. Barclays PLC now owns 768,078 shares of the biotechnology company's stock worth $1,161,000 after acquiring an additional 579,657 shares during the period. Weiss Multi Strategy Advisers LLC bought a new position in OPKO Health during the fourth quarter worth about $1,057,000. Finally, Royal Bank of Canada increased its position in OPKO Health by 19.8% during the fourth quarter. Royal Bank of Canada now owns 304,411 shares of the biotechnology company's stock worth $460,000 after acquiring an additional 50,248 shares during the period. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.